OverviewSuggest Edit

Halozyme Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. The company offers its proprietary enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids and forms the basis of ENHANZE drug delivery technology platform that enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. In addition, the company markets Hylenex recombinant (hyaluronidase human injection), which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
TypePublic
Founded1998
HQSan Diego, CA, US
Websitehalozyme.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Feb 2021)136(+4%)
Job Openings9
Revenue (FY, 2020)$267.6 M(+37%)
Share Price (Jul 2021)$42.1
Cybersecurity ratingCMore

Key People/Management at Halozyme Therapeutics

Helen Torley

Helen Torley

President, Chief Executive Officer and Member of the Board of Directors
Mas Matsuda

Mas Matsuda

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Michael J. LaBarre

Michael J. LaBarre

Senior Vice President, Chief Technical Officer
Steve Knowles

Steve Knowles

Chief Medical Officer
Todd Butler

Todd Butler

Chief of Staff to the CEO, Vice President, Head of Project Management
Elaine Sun

Elaine Sun

Senior Vice President, Chief Financial Officer
Show more

Halozyme Therapeutics Office Locations

Halozyme Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
11388 Sorrento Valley Rd
Show all (1)

Halozyme Therapeutics Financials and Metrics

Halozyme Therapeutics Revenue

Embed Graph
View revenue for all periods
Halozyme Therapeutics's revenue was reported to be $267.59 m in FY, 2020 which is a 36.5% increase from the previous period.
USD

Revenue (Q1, 2021)

89.0m

Gross profit (Q1, 2021)

70.8m

Gross profit margin (Q1, 2021), %

79.5%

Net income (Q1, 2021)

27.9m

EBIT (Q1, 2021)

50.7m

Market capitalization (21-Jul-2021)

6.0b

Closing stock price (21-Jul-2021)

42.1

Cash (31-Mar-2021)

499.5m

EV

6.4b
Halozyme Therapeutics's current market capitalization is $6 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

151.9m196.0m267.6m

Revenue growth, %

29%37%

Cost of goods sold

10.1m45.5m43.4m

Gross profit

141.7m150.4m224.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

56.9m39.1m46.2m25.4m55.2m65.3m89.0m

Cost of goods sold

4.6m1.9m22.3m5.8m5.7m5.6m18.2m

Gross profit

52.3m37.3m23.9m19.6m49.5m59.7m70.8m

Gross profit Margin, %

92%95%52%77%90%91%80%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

57.9m120.2m147.7m

Accounts Receivable

30.0m59.4m97.7m

Prepaid Expenses

20.7m33.4m28.3m

Inventories

22.6m29.4m60.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

60.6m67.0m59.2m104.8m133.6m65.7m499.5m

Accounts Receivable

28.2m32.2m40.7m29.7m37.4m62.6m88.4m

Prepaid Expenses

20.9m28.1m27.2m28.6m29.2m31.9m30.7m

Inventories

31.2m43.9m36.1m41.5m48.3m57.7m58.3m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(80.3m)(72.2m)129.1m

Depreciation and Amortization

2.4m4.1m3.3m

Inventories

(17.5m)(6.7m)(31.4m)

Accounts Payable

5.7m4.6m(41.2m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

1.8m(12.8m)(37.8m)(6.1m)19.7m55.9m27.9m

Depreciation and Amortization

990.0k2.0m3.0m857.0k1.7m2.5m738.0k

Inventories

(8.6m)(21.3m)(13.4m)(12.1m)(18.9m)(28.3m)2.5m

Accounts Payable

(7.9m)1.7m(6.8m)(27.6m)(37.5m)(40.1m)(6.6m)
USDFY, 2018

EV/EBIT

-31.5 x

EV/CFO

-44.1 x

Revenue/Employee

595.5k

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x

P/E Ratio

(26.1)
Show all financial metrics

Halozyme Therapeutics Operating Metrics

FY, 2018FY, 2019FY, 2020

Products

111

Partnered Products

335

Filed Trials Products

2

Phase III Trials Products

538
Show all operating metrics

Halozyme Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Halozyme Holdings Ltd.
Halozyme, Inc.
Halozyme Switzerland GmbH
Halozyme Switzerland Holdings GmbH

Halozyme Therapeutics Revenue Breakdown

Embed Graph

Halozyme Therapeutics revenue breakdown by business segment: 10.5% from Product Sales, 16.6% from Royalties, 23.0% from Revenues under Collaborative Agreements, 10.5% from Product Sales, 16.6% from Royalties and 23.0% from Revenues under Collaborative Agreements

Halozyme Therapeutics revenue breakdown by geographic segment: 7.5% from Belgium, 35.9% from Switzerland, 40.0% from United States, 11.4% from Ireland and 5.3% from Other

Human Capital Metrics

Halozyme Therapeutics's employees are reported to be approximately 52% female and 48% male.
Embed Graph
Show all human capital metrics

Halozyme Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Halozyme Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Halozyme Therapeutics Online and Social Media Presence

Embed Graph

Halozyme Therapeutics News and Updates

ViiV Healthcare, Halozyme partner to develop HIV medicines

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV.

Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Piper Sandler

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating in a report released on Tuesday, Briefing.com reports. They presently have a $48.00 price target on the biopharmaceutical company's stock, down from their previous price …

Halozyme Reports First Quarter 2021 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent corporate activities and outlook

Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time

Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial res…

Halozyme Therapeutics Inc (HALO) President and CEO Helen Torley Sold $2.3 million of Shares

President and CEO of Halozyme Therapeutics Inc (30-Year Financial, Insider Trades) Helen Torley (insider trades) sold 50,000 shares of HALO on 03/01/2021 at an average price of $46.19 a share. The total sale was $2.3 million.
Show more

Halozyme Therapeutics Frequently Asked Questions

  • When was Halozyme Therapeutics founded?

    Halozyme Therapeutics was founded in 1998.

  • Who are Halozyme Therapeutics key executives?

    Halozyme Therapeutics's key executives are Helen Torley, Mas Matsuda and Michael J. LaBarre.

  • How many employees does Halozyme Therapeutics have?

    Halozyme Therapeutics has 136 employees.

  • What is Halozyme Therapeutics revenue?

    Latest Halozyme Therapeutics annual revenue is $267.6 m.

  • What is Halozyme Therapeutics revenue per employee?

    Latest Halozyme Therapeutics revenue per employee is $2 m.

  • Who are Halozyme Therapeutics competitors?

    Competitors of Halozyme Therapeutics include Partner Therapeutics, Verastem Oncology and Rakuten Medical.

  • Where is Halozyme Therapeutics headquarters?

    Halozyme Therapeutics headquarters is located at 11388 Sorrento Valley Rd, San Diego.

  • Where are Halozyme Therapeutics offices?

    Halozyme Therapeutics has an office in San Diego.

  • How many offices does Halozyme Therapeutics have?

    Halozyme Therapeutics has 1 office.